CEL-SCI logo

CVM - CEL-SCI News Story

$12.49 0.3  2.3%

Last Trade - 9:10pm

Sector
Healthcare
Size
Mid Cap
Market Cap £356.1m
Enterprise Value £350.7m
Revenue £457k
Position in Universe 3091st / 6432

BRIEF-Cel-Sci Announces Early Results With Covid 19 Leaps Vaccine/Treatment

Fri 24th July, 2020 1:39pm
July 24 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI ANNOUNCES EARLY RESULTS WITH COVID 19 LEAPS
VACCINE/TREATMENT
    * CEL-SCI CORP - CONCLUDED ANIMAL EXPERIMENTS USING ITS
LEAPS
COVID 19 CONJUGATE
    * CEL-SCI CORP - IGG ANTIBODIES RESPONSE WAS GENERATED
WITHIN 10
DAYS OF A SINGLE IMMUNIZATION IN STUDY
    * CEL-SCI - ANIMAL EXPERIMENTS SHOWED LEAPS CONJUGATES
INDUCED
FASTER, HIGHER THAN EXPECTED ANTIBODY RESPONSES AGAINST A
NON-MUTATING REGION OF VIRUS
    * CEL-SCI CORP -  LEAPS COVID 19 CONJUGATES INDUCED FASTER &
MUCH
HIGHER THAN EXPECTED ANTIBODY RESPONSES AFTER ONLY ONE INJECTION
    * CEL-SCI-SARS-COV-2 CHALLENGE STUDIES SEEK TO REPEAT
SUCCESS OF
ANIMAL CHALLENGE STUDIES CONDUCTED PREVIOUSLY AT NIH/NIAID
EMERGING DISEASES LABORATORY

Source text for Eikon:  ID:nBw2h6hG1a 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.